Riskpilot← Back to searchSign inGet full accessINSULIFE AS
ASActiveOrg 925128554Gaustadalléen 21, 0349 OsloManufacture of pharmaceutical preparations · NACE 2120Est. 20205 employeeswww.insulife.com
Revenue 2024
NOK 56K
EBITDA margin
-23243.4%
+11% vs 2023
Equity ratio
77.0%
Financial strength
Net profit 2024
NOK -12,9M
+11% vs 2023
| Revenue | NOK 56K | — |
| EBITDA | NOK -13M | +11% |
| Net profit | NOK -12,9M | +11% |
| Total assets | NOK 28,7M | -2% |
| Equity | NOK 22,1M | -12% |
| Employees | 5 | — |
Legal name
INSULIFE AS
Org number
925128554
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
5. juni 2020
Share capital
NOK 72 403
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikle, eie, produsere, markedsføre og drive salg av spray baserte legemidler samt det som står i forbindelse med dette. Selskapet skal også kunne delta i andre virksomheter med økonomiske formål.
Address
Gaustadalléen 21, 0349 Oslo
Website
www.insulife.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 56 |
| Staff expenses | −351 | −3 561 | −5 747 | −5 876 | −6 877 |
| EBITDA | −632 | −4 599 | −9 143 | −14 674 | −13 016 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −632 | −4 599 | −9 143 | −14 674 | −13 016 |
| Net financials | 46 | −14 | 475 | 164 | 119 |
| Profit before tax | −586 | −4 613 | −8 668 | −14 511 | −12 897 |
| Tax | −139 | 139 | −0 | −0 | −0 |
| Net profit | −447 | −4 752 | −8 668 | −14 511 | −12 897 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 595 | 11 341 | 31 438 | 29 125 | 28 665 |
| Equity | 1 533 | 9 299 | 29 088 | 25 053 | 22 071 |
| Long-term debt | 0 | 0 | 595 | 1 490 | 978 |
| Short-term debt | 2 062 | 2 042 | 1 755 | 2 582 | 5 617 |
| Total debt | 2 062 | 2 042 | 2 350 | 4 072 | 6 594 |
EBITDA margin
-23243.4%
This company
15.8%
Market median
-147210% vs market
20202024
Equity ratio
77.0%
This company
38.2%
Market median
+102% vs market
20202024
Return on equity
-58.4%
This company
18.4%
Market median
-417% vs market
20202024
Net profit margin
-23030.0%
This company
8.1%
Market median
-284421% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-03-31 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ÅN Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Chairman | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 25.5% | 25.5% | 2022 | |
Wessel Capital Llc | Company | 23.8% | 23.8% | 2024 |
Transdermal Delivery Solutions Cor | Company | 22.2% | 22.2% | 2024 |
Pharmamentor As | Company | 8.5% | 8.5% | 2024 |
Siro Clinpharm Private Limited | Company | 3.5% | 3.5% | 2024 |
Scanpipe Engineering As | Company | 3.2% | 3.2% | 2024 |
Silvercoin Industries As | Company | 2.8% | 2.8% | 2024 |
Skadi As | Company | 2.8% | 2.8% | 2024 |
3t Holding As | Company | 2.1% | 2.1% | 2024 |
Smerud Medical Research International As | Company | 1.7% | 1.7% | 2024 |
| Individual | 1.4% | 1.4% | 2024 | |
Konstrukt Holding As | Company | 1.2% | 1.2% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of INSULIFE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Åge Nærdal | Chief Executive Officer | 0 companies |
| Per Heiberg Dybwad | Deputy Chairman | 0 companies |
| Pål Eriksen | Board of Directors | 0 companies |
| Gregory David Cash | Board of Directors | 0 companies |
| Kari Struksnes | Board of Directors | 0 companies |
| Bjørg Eikeland | Board of Directors | 0 companies |
| Eric Cameron | Chairman | 0 companies |
| Petter Wessel Bjornstad | Chairman | 0 companies |
| Rolf Viggo Leisner | Board of Directors | 0 companies |
| Anne Waaler | Board of Directors | 0 companies |
| David Weild Iv | Board of Directors | 0 companies |
| Kenneth Bruce Kirby | Board of Directors | 0 companies |
| Bert Joseph Moerings | Board of Directors | 0 companies |